Esketamine receives US FDA approval for treatment-resistant depression

Written by Ebony Torrington (Future Science Group)

The US FDA (MD, USA) has recently approved a new antidepressant termed, Spravato™ (esketamine) nasal spray, along with an oral antidepressant, for treatment-resistant depression in adults. Spravato is the first major new depression treatment to be approved by the FDA since Prozac hit the market more than 30 years ago, according to a report from the NPR. People are considered to have treatment-resistant depression if they have tried at least two antidepressant treatments in an episode, for an adequate duration with an adequate dose, but have not responded to the treatment. “There has been a long-standing need for additional effective...

To view the full article, please register now for access

It's completely free